Epigenic Therapeutics to present preclinical update of company's epigenome modulation technology for elimination of HBV viral antigens at 2024 annual conference of the European Association for the Study of the Liver
Shanghai, China, 10 May 2024- Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, announced acceptance of an oral presentation at the European Association for the Study of the Liver (EASL) to be held in Milan, Italy, 5-8 June 2024. The presentation is entitled “Efficient and heritable elimination of HBV viral antigens in vivo by epigenome editing”.
EPIREGTM, Epigenic’s proprietary core technology of epigenome regulation, offers a compelling alternative to the traditional cleavage-dependent gene editing tools. By precisely modulating gene expression(s) at epigenetic levels, EPIREGTMis expected to achieve potent and durable silencing of target gene(s), thus providing revolutionary and novel solutions to patients with chronic diseases.
The oral presentation will report the preclinical achievements of EPI-003, an anti-HBV clinical development candidate, utilizing EPIREGTMto specifically block the tranion of both HBV cccDNA and genome-integrated HBV DNA, ultimately eliminating HBsAg and inducing serological conversion. The preclinical data in HBV-infected primary human hepatocytes and animal models reveals EPI-003, as the first and best-in-class anti-HBV profiles, has great potential for clinical functional or complete cure of HBV in patients with chronic hepatitis B infection.
Oral presentation Number: 850
Final abstract identifier: OS-093
Session-Viral Hepatitis: Experimental and pathophysiology
Presentation Date and Time: 17:15-18:30, 6 June 2024 (CET)
About Epigenic Therapeutics
Epigenic Therapeutics is a frontier biotechnology company dedicated to developing next generation gene editing therapy utilizing regulation of epigenetic genome for a variety of diseases. Founded in 2021 by leading scientists focused on discovering gene editing technologies and developing gene editing therapies, the company has multiple product candidates in the pipeline, including treatment for ocular, neurodegeneration, metabolic, and rare diseases. For more information, visit www.epigenictx.com
Contact
